Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase 1/2 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5

Conditions

Neuroblastoma 5Prostatic Neoplasms 3Skin Neoplasms 2Precancerous Conditions 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Stomach Neoplasms 1Sarcoma, Ewing 1Osteosarcoma 1Non-melanoma Skin Cancer 1Neoplasms 1Medulloblastoma 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1Adenomatous Polyps 1Adenomatous Polyposis Coli 1

Interventions

Cyclophosphamide 34Etoposide 25Doxorubicin 20Carboplatin 20Vincristine 19Isotretinoin 19Topotecan 17Temozolomide 17Irinotecan 16Filgrastim 16Melphalan 15Cisplatin 15sargramostim 14Radiotherapy 14Granulocyte-Macrophage Colony-Stimulating Factor 133-Iodobenzylguanidine 12dinutuximab 11Peripheral Blood Stem Cell Transplantation 11naxitamab 9Thiotepa 9Magnetic Resonance Spectroscopy 9humanized 3F8 anti-GD2 monoclonal antibody 7Granulocyte Colony-Stimulating Factor 7Busulfan 7X-Rays 6Specimen Handling 6Phantoms, Imaging 6Ifosfamide 6Antilymphocyte Serum 6fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Neuroblastoma × Eflornithine × Clear all
NCT02559778 2026-04-28

PEDS-PLAN

Milton S. Hershey Medical Center

Phase 2 Recruiting
500 enrolled
CNS

Neuroblastoma

NCT03794349 2026-02-18

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Children's Oncology Group

Phase 2 Active not recruiting
94 enrolled 14 charts
CNS

Neuroblastoma

NCT04301843 2026-02-03

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
131 enrolled
CNS

Neuroblastoma

NCT02679144 2026-01-21

NMTT

Milton S. Hershey Medical Center

Phase 2 Recruiting
441 enrolled
CNS

Neuroblastoma

NCT02395666 2024-08-06

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

Milton S. Hershey Medical Center

Phase 2 Completed
140 enrolled 14 charts 1 FDA
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡